Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid.
Acyclovir
/ therapeutic use
Antiviral Agents
/ therapeutic use
Betacoronavirus
/ genetics
Brain
/ diagnostic imaging
COVID-19
Coronavirus Infections
/ cerebrospinal fluid
Female
Glial Fibrillary Acidic Protein
/ cerebrospinal fluid
Humans
Immunoglobulins, Intravenous
/ therapeutic use
Immunologic Factors
/ therapeutic use
Interleukin-6
/ cerebrospinal fluid
Leukoencephalitis, Acute Hemorrhagic
/ cerebrospinal fluid
Magnetic Resonance Imaging
Middle Aged
Neurofilament Proteins
/ cerebrospinal fluid
Pandemics
Plasma Exchange
Pneumonia, Viral
/ cerebrospinal fluid
RNA, Viral
/ cerebrospinal fluid
Real-Time Polymerase Chain Reaction
SARS-CoV-2
Tomography, X-Ray Computed
Viral Tropism
tau Proteins
/ cerebrospinal fluid
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
08 09 2020
08 09 2020
Historique:
received:
14
05
2020
accepted:
19
06
2020
pubmed:
27
6
2020
medline:
18
9
2020
entrez:
27
6
2020
Statut:
ppublish
Résumé
Here, we report a case of COVID-19-related acute necrotizing encephalopathy where SARS-CoV-2 RNA was found in CSF 19 days after symptom onset after testing negative twice. Although monocytes and protein levels in CSF were only marginally increased, and our patient never experienced a hyperinflammatory state, her neurologic function deteriorated into coma. MRI of the brain showed pathologic signal symmetrically in central thalami, subinsular regions, medial temporal lobes, and brain stem. Extremely high concentrations of the neuronal injury markers neurofilament light and tau, as well as an astrocytic activation marker, glial fibrillary acidic protein, were measured in CSF. Neuronal rescue proteins and other pathways were elevated in the in-depth proteomics analysis. The patient received IV immunoglobulins and plasma exchange. Her neurologic status improved, and she was extubated 4 weeks after symptom onset. This case report highlights the neurotropism of SARS-CoV-2 in selected patients and emphasizes the importance of repeated lumbar punctures and CSF analyses in patients with suspected COVID-19 and neurologic symptoms.
Identifiants
pubmed: 32586897
pii: WNL.0000000000010250
doi: 10.1212/WNL.0000000000010250
pmc: PMC7538220
doi:
Substances chimiques
Antiviral Agents
0
Glial Fibrillary Acidic Protein
0
Immunoglobulins, Intravenous
0
Immunologic Factors
0
Interleukin-6
0
Neurofilament Proteins
0
RNA, Viral
0
neurofilament protein L
0
tau Proteins
0
Acyclovir
X4HES1O11F
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
445-449Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Emerg Infect Dis. 2004 Feb;10(2):342-4
pubmed: 15030709
Radiology. 2020 Aug;296(2):E119-E120
pubmed: 32228363
Virology. 1992 May;188(1):274-84
pubmed: 1314455
Virology. 1989 Jun;170(2):556-60
pubmed: 2543129
Int J Infect Dis. 2020 May;94:55-58
pubmed: 32251791
J Med Virol. 2020 Jul;92(7):699-702
pubmed: 32314810
Brain Dev. 1997 Mar;19(2):81-92
pubmed: 9105653